Sanofi: new positive phase II results in MS

(CercleFinance.com) - Sanofi reports new 48-week Phase II results for frexalimab, its investigational anti-CD40L antibody, confirming the potential for high and sustained efficacy in the treatment of multiple sclerosis (MS).


Frexalimab achieved a sustained reduction in disease activity and showed favourable tolerability after one year of treatment in a clinical trial in participants with relapsing-remitting MS.

These results will be presented at the AAN Annual Meeting in Denver, Colorado today. Sanofi has begun international Phase III clinical trials of frexalimab in the treatment of relapsing-remitting and secondarily progressive MS.


Copyright (c) 2024 CercleFinance.com. All rights reserved.